Guard Therapeutics International AB (DE:5LH0)
FRANKFURT:5LH0
5LH0 Stock Chart & Stats
€0.04
€0.06(3.57%)
At close: 4:00 PM EST
€0.04
€0.06(3.57%)
Day’s Range― - ―
52-Week Range€0.01 - €2.27
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€2.51M
Enterprise Value-€22.40M
Total Cash (Recent Filing)€100.48M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta1.57
Next Earnings
May 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding20,167,631
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.65
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.1
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
No DebtHaving no debt materially reduces refinancing and interest-service pressure for a clinical-stage biotech. This gives management more strategic flexibility to prioritize R&D and partnerships rather than near-term cash interest obligations, lowering one structural source of financial risk.
A1M Platform FocusA clearly articulated, platform-oriented science (A1M) focused on kidney diseases supports a durable strategic position. A platform can enable multiple indications, create repeatable R&D value, and improve licensing or partnership prospects versus single-product approaches over the medium term.
Earnings Reflect Real Cash BurnOperating cash flows that align with reported losses imply limited non-cash accounting distortion, improving earnings quality. For investors and partners this transparency aids reliable runway and financing modelling, a useful structural attribute for a loss-making developer.
Bears Say
No RevenueA five-year absence of revenue signals the company remains pre-commercial and dependent on successful clinical progress or deals to generate sales. That extends timeline to durable cash generation and raises long-term execution and commercialization risk for investors and partners.
Sustained Cash BurnLarge, persistent negative operating cash flow (e.g., -109.4M in 2025) depletes resources and forces repeated financing. Over a multi-quarter horizon this elevates dilution and execution risk, limiting the company's ability to independently fund pivotal trials or scale development programs.
Eroding Balance SheetRapid depletion of assets and equity reduces the firm's financial buffer against clinical setbacks or longer development timelines. A weaker balance sheet constrains strategic optionality, increases dependence on external capital, and magnifies the consequences of future adverse outcomes.
5LH0 FAQ
What was Guard Therapeutics International AB’s price range in the past 12 months?
Guard Therapeutics International AB lowest stock price was €0.01 and its highest was €2.27 in the past 12 months.
What is Guard Therapeutics International AB’s market cap?
Guard Therapeutics International AB’s market cap is €2.51M.
When is Guard Therapeutics International AB’s upcoming earnings report date?
Guard Therapeutics International AB’s upcoming earnings report date is May 13, 2026 which is in 38 days.
How were Guard Therapeutics International AB’s earnings last quarter?
Guard Therapeutics International AB released its earnings results on Feb 20, 2026. The company reported -€0.075 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.075.
Is Guard Therapeutics International AB overvalued?
According to Wall Street analysts Guard Therapeutics International AB’s price is currently Overvalued.
Does Guard Therapeutics International AB pay dividends?
Guard Therapeutics International AB does not currently pay dividends.
What is Guard Therapeutics International AB’s EPS estimate?
Guard Therapeutics International AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Guard Therapeutics International AB have?
Guard Therapeutics International AB has 20,167,631 shares outstanding.
What happened to Guard Therapeutics International AB’s price movement after its last earnings report?
Guard Therapeutics International AB reported an EPS of -€0.075 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Guard Therapeutics International AB?
Currently, no hedge funds are holding shares in DE:5LH0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Guard Therapeutics International AB
Guard Therapeutics International AB (publ), a pharmaceutical company, identifies, develops, and commercializes therapies for the diagnosis and treatment of acute kidney injuries in Sweden. It offers ROSGard, a biological drug candidate that prevents kidney damage by protecting, cleaning, and repairing the exposed cells and tissues. The company was formerly known as A1M Pharma AB (publ) and changed its name to Guard Therapeutics International AB (publ) in October 2019. Guard Therapeutics International AB (publ) was incorporated in 2008 and is based in Stockholm, Sweden.
Technical Analysis
Xbrane Biopharma AB
―
Ascelia Pharma AB
―
Intervacc AB
―
Immunicum AB
―
Corline Biomedical AB
―